Ubs Oconnor LLC Uni Qure N.V. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Uni Qure N.V. stock. As of the latest transaction made, Ubs Oconnor LLC holds 198,223 shares of QURE stock, worth $3.37 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

198,223

Holding current value

$3.37 Million

% of portfolio

0.07%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.78 - $10.12 $65,333 - $174,914	17,284 Added 9.55%	198,223 $977,000
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $482,351 - $596,621	109,875 Added 154.61%	180,939 $810,000
Q1 2024 May 15, 2024	SELL	$4.82 - $6.93 $115,371 - $165,876	-23,936 Reduced 25.2%	71,064 $369,000
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $33,977 - $49,909	6,035 Added 6.78%	95,000 $643,000
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $369,050 - $650,650	-55,000 Reduced 38.2%	88,965 $596,000
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $1.6 Million - $3.2 Million	143,965 New	143,965 $1.65 Billion
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $749,402 - $924,530	40,075 Added 114.5%	75,075 $1.51 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $634,200 - $956,200	35,000 New	35,000 $0

Others Institutions Holding QURE

# of Institutions

154

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

Vestal Point Capital, LP New York, NY

4.75M
Shares

$80.7 Million
1.78% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.78M
Shares

$47.2 Million
0.81% of portfolio
Boxer Capital, LLC San Diego, CA

2.23M
Shares

$37.8 Million
0.58% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.19M
Shares

$37.2 Million
0.01% of portfolio
Abrdn PLC

1.93M
Shares

$32.8 Million
0.02% of portfolio

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $793M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account